Page last updated: 2024-12-06

isopropyl glycidyl ether

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

isopropyl glycidyl ether: RN & structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID19920
CHEMBL ID1487011
SCHEMBL ID39030
MeSH IDM0228468

Synonyms (77)

Synonym
EN300-22498
IGE ,
isopropyl glycidyl ether
glycidyl isopropyl ether
4016-14-2
propane,2-epoxy-3-isopropoxy-
(isopropoxymethyl)oxirane
nsc-4127
wln: t3otj b1oy1&1
3-isopropyloxypropylene oxide
nsc4127
oxirane, [(1-methylethoxy)methyl]-
3-isopropoxy-1,2-epoxypropane
nci-c56439
propane, 1,2-epoxy-3-isopropoxy-
nsc-46562
nsc46562
ccris 2631
hsdb 4302
isopropyl glycidyl ether ige
1,2-epoxy-3-isopropoxypropane
2,3-epoxypropyl isopropyl ether
nsc 46562
((1-methylethoxy)methyl)oxirane
nsc 4127
isopropyl epoxypropyl ether
oxirane, ((1-methylethoxy)methyl)-
2,3-epoxypropyl-isopropyl ether
ai3-52929
brn 0103028
einecs 223-672-9
NCGC00091815-01
glycidyl isopropyl ether, 98%
2-(isopropoxymethyl)oxirane
2-(propan-2-yloxymethyl)oxirane
inchi=1/c6h12o2/c1-5(2)7-3-6-4-8-6/h5-6h,3-4h2,1-2h3
nwluzgjdezbbrh-uhfffaoysa-
AKOS000196880
MLS002454412
smr001372011
G0255
2-[(propan-2-yloxy)methyl]oxirane
STK802341
NCGC00091815-02
HMS3039F15
unii-1v3116630g
oxirane, 2-((1-methylethoxy)methyl)-
1v3116630g ,
dtxcid705480
dtxsid6025480 ,
tox21_200038
cas-4016-14-2
NCGC00257592-01
isopropyl glycidyl ether [hsdb]
(isopropyloxymethyl)oxirane
glycidyl isopropyl ether, (+/-)-
2-((1-methylethoxy)methyl)oxirane
AKOS017283448
CHEMBL1487011
isopropylglycidyl ether
2-[(1-methylethoxy)methyl]oxirane
BBL027498
SCHEMBL39030
oxirane, 2-[(1-methylethoxy)methyl]-
2-(isopropoxymethyl)oxirane #
1,2-epoxy-3-iso-propoxypropane
glycidyl isopropyl ether purum
mfcd00005139
glycidyl isopropyl ether, purum, >=98.0% (gc)
FT-0761964
F0001-1133
Q2803610
VS-08554
glycidylisopropylether
E78219
Z147642824
SY051643

Research Excerpts

Treatment

ExcerptReferenceRelevance
"The isopropyl glycidyl ether treatment of wood was effective in decreasing formation of phenoxyl radicals upon UV irradiation and thus protecting wood from photodiscoloration."( Modification of wood with isopropyl glycidyl ether and its effects on decay resistance and light stability.
Chang, HT; Chang, ST, 2006
)
1.11
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.01710.006038.004119,952.5996AID1159521
TDP1 proteinHomo sapiens (human)Potency4.61090.000811.382244.6684AID686978
GLI family zinc finger 3Homo sapiens (human)Potency61.02570.000714.592883.7951AID1259369; AID1259392
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency60.99880.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.48670.000229.305416,493.5996AID743075
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
heat shock protein beta-1Homo sapiens (human)Potency61.27540.042027.378961.6448AID743210
gemininHomo sapiens (human)Potency12.43470.004611.374133.4983AID624296; AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (11.11)18.2507
2000's3 (33.33)29.6817
2010's4 (44.44)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.84 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]